Chardan Capital Reiterates Buy Rating on Arrowhead Pharmaceuticals, Inc. (ARWR)
Rating Change Chardan Capital analysts reiterated a Buy rating on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) on July 22, 2026. Market Context Arrowhead Pharmaceuticals, Inc.
Read more
